

Note: [01 Mar 2017] – The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative.

FORM 13-501F1
CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS –
PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, Mark Upsdell, an officer of the reporting issuer noted below have examined this Form 13-501F1 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

Mark Upsdell - CEO

August 24, 2021

Name: Mark Upsdell

Date: _____

Title: CEO

Reporting Issuer Name: _____

Rapid Dose Therapeutics Corp.

End date of previous financial year: _____

February 29, 2021

Type of Reporting Issuer:

Class 1 reporting issuer

Class 3B reporting issuer

Highest Trading Marketplace: _____

Canadian Securities Exchange

Market value of listed or quoted equity securities:

Equity Symbol _____

DOSE

1st Specified Trading Period (dd/mm/yy) _____

01/03/2020

to

31/05/2020

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ _____ .25
(i)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period 77,067,435

(ii)

Market value of class or series

(i) x (ii)

\$ 19,266,858.75
(A)

2nd Specified Trading Period (dd/mm/yy)

01/06/2020 to 31/08/2020

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$.33
(iii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

77,067,435
(iv)

Market value of class or series

(iii) x (iv)

\$ 24,532,253.55
(B)

3rd Specified Trading Period (dd/mm/yy)

01/09/2020 to 30/11/2020

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$.34
(v)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

80,866,805
(vi)

Market value of class or series

(v) x (vi)

\$ 27,494,731.07
(C)

4th Specified Trading Period (dd/mm/yy)

01/12/2020 to 28/02/2021

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ _____ .21
(vii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

80,866,805

(viii)

Market value of class or series

(vii) x (viii) \$ 16,982,029.05

(D)

5th Specified Trading Period (dd/mm/yy)

_____ to _____

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ _____
(ix)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

(x)

Market value of class or series

(ix) x (x) \$ _____
(E)

Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))

\$ 22,068,968.19

(1)

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined)

\$ _____
(2)

Capitalization for the previous financial year

(1) + (2)

\$ 22,068,968.19

Participation Fee

\$ 500

Late Fee, if applicable

\$ _____

Total Fee Payable

(Participation Fee plus Late Fee)

\$ 500